Condition: Healthy Volunteers · Pancreatic Ductal Adenocarcinoma · Non-small Cell Lung Cancer (NSCLC) · Sponsor: Radiopharm Theranostics, Ltd
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
This description comes directly from the study's public registry record.
Dimitris Voliotis, MD · +1 646 535 5017 · dv@radiopharmtheranostics.com
Always discuss trial participation with your own doctor first.
| United Theranostics | Princeton, New Jersey, United States | Terminated |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05799274